Sentences with phrase «tumor antigens»

In a 2009 paper published in Nature Materials, Mooney demonstrated that this could be achieved by loading a porous scaffold — about the size of a dime — with tumor antigen as well as a combination of biological and chemical components meant to attract and activate dendritic cells.

The team also created an ImmunoMap of the diversity of T - cell receptors specific for tumor antigens in mice with and without tumors.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

Bladder tumor antigen tests on the urine may suggest a diagnosis of bladder cancer, but definitive diagnosis is possible only with a biopsy.

A urine bladder tumor antigen test has been developed and is an excellent screening test to rule out bladder cancer.

He also studies the mechanisms of antigen presentation to T cells, the impact of immunoregulation on tumor antigen - specific responses, and characterization of the tumor - immune microenvironment.

These are more specific therapies such as monoclonal antibodies and cancer vaccines, which target specific tumor antigens.

The infection releases tumor antigens in a way that jump - starts the immune response.»

This has involved preclinical and clinical evaluation in Phase I and Phase I / II studies that have characterized tumor antigen expression and immune responses in patients.

We believe that when G100 is administered with mechanisms that kill, or lyse, tumor cells (such as radiation), it may cause dendritic cells near the lysed tumor to activate and capture the wide range of released endogenous tumor antigens.

In addition, because ZVex product candidates have the potential to carry the genetic material of different tumor antigens, as well as immunostimulatory molecules, we can design them to target multiple types of cancers.

She has obtained intramural support through the Vanderbilt Physician Scientist Development (VPSD) Award Program and a Cancer Center Grant Support (CCSG) Award to identify relevant tumor antigens / targets in breast cancer tumor samples.

The Jantibody fusion protein, combining an antibody fragment targeting an antigen found on tumor cells with an immune - response - inducing protein, MTBhsp70, activates dendritic cells against several tumor antigens and induces a number of T - cell - based immune responses.

Another version, the CTC - iChip, rapidly isolates CTCs in a way that does not rely on preidentified tumor antigens, allowing capture of cells with gene expression patterns that may be missed by the antibodies used in the HBCTC - Chip.

«Our findings suggest that genetically altering tumor cells to produce IL - 15 and IL - 15Rα can cause and enhance immune responses to tumor antigens found in these tumor cells and can be used as a vaccine to target these antigens.

Early - stage data suggests the investigative LAMP - Vax technology works by fusing tumor antigens to a cellular protein known as LAMP (Lysosomal - Associated Membrane Protein).

Singlet oxygen tends to rip apart tumor cells in a manner that exposes many new tumor antigens to immune cells called dendritic cells, which, like police executing a dragnet, grab the antigens and present them to T cells for closer inspection.

Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P. Somatically mutated tumor antigens in the quest for a more efficacious patient - oriented immunotherapy of cancer.

Treatment with HSV1 - TK is expected to kill transduced brain cells, thus exposing tumor antigen.

Tsuji T, Matsuzaki J, Caballero OL, Jungbluth AA, Ritter G, Odunsi K, Old LJ, Gnjatic S. (2012) Heat shock protein 90 - mediated peptide - selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4 + T cells.

Recently she characterized anti-tumor effects of a unique human CD4 + helper T - cell subset that directly recognizes the cytoplasmic tumor antigen, NY - ESO - 1, presented by MHC class II on cancer cells.

They do, however, play a key role in helping to boost the anti-tumor immune response by: (1) expanding the number and improving the function of existing CTLs that are specific to the same tumor antigen; and (2) providing help to other immune cells, including B lymphocytes that are precursors to antibodies and natural killer (NK) cells that are also important in the overall anti-tumor immune response.

«We have created a potentially much less expensive approach to making a therapeutic cancer vaccine that, while targeting a single tumor antigen, generates an immune response against multiple antigens.

As noted above, existing cancer vaccines that use dendritic cells require extracting cells from a patient's blood, treating them with an engineered protein or nucleic acid that combines tumor antigens with immune - stimulating molecules, and returning the activated dendritic cells to the patient.

Also, CMB305 was well tolerated, and generated a strong and broad anti-NY-ESO-1 immune response in > 50 % of the patients, including evidence of antigen spreading — the induction of an immune response against other tumor antigens not targeted by CMB305.

NY - ESO - 1 is one of the few tumor antigens that have restricted expression in normal tissue but become aberrantly expressed in epithelial ovarian cancers and other solid tumors.

These results suggest that tumor antigen loaded CD40 - B may serve as a practical alternative to DC in cell - based vaccine strategies for both dogs and humans with cancer.

The CNIC research team generated cytotoxic memory T cells specifically targeting cancer by using different methods for vaccination with tumor antigens.

The CRI also maintains the Peptide Database, which contains the most important and clinically relevant human tumor antigens.

Instead, it relies on endogenous tumor antigens that are released during tumor lysis by treatments such as chemotherapy or local radiation.

In the experiments described in the paper, the MGH team confirmed that their mesothelin - targeting fusion protein binds to mesothelin on either ovarian cancer or mesothelioma cells, activates dendritic cells, and enhances the cells» processing and presentation of several different tumor antigens, inducing a number of T - cell - based immune responses.

It is commonly diagnosed through a combination of urinalysis, urine sediment cytology, bladder tumor antigen testing, x-rays and / or ultrasound, and tissue biopsy.

If a bladder tumor antigen test is positive, then further ultrasound and tissue biopsy will be necessary to make a definitive diagnosis and guide specific therapy.

Instead of targeting specific tumor antigens, this approach relies on endogenous antigens (including neoantigens) released during tumor lysis by treatments such as chemotherapy or local radiation.

Dr. Odunsi has made significant research contributions, which include the characterization of tumor antigens and then using them to develop immunotherapy vaccines for ovarian cancer patients.

While higher TIL levels conferred a favorable prognosis in patients with spontaneous immune response to tumor antigens, they were a poor prognostic factor in patients who did not experience an immune response.

One of the 43 began producing a new protein, which the researchers took to be an antibody to the tumor antigen.

The remaining one - third of patients, composing a control group, received injections of their own dendritic cells that were not exposed to tumor antigens.

In this study, we examined the effectiveness of a vaccination targeting tumors that produced IL - 15 and its cell surface receptor called IL - 15R - alpha -LRB--RRB- and examined their ability to up - regulate (or increase) immune responses to tumor antigens,» Morris says.

The light - sensitive cells and nanoparticles, called opto - CRAC, were then delivered with the tumor antigen surrogate ovalbumin to mice with melanoma tumors in their lymph nodes to see if an immune response could be activated to target cancer cells.

A tumor antigen, such as ovalbumin, is needed to program newly activated T - cells with their intended target.